Oncology

Drug Name

• “Real-World” Data Show Improved Outcomes With Personalized Multidrug Therapy: I-PREDICT
• A Growing Focus on Rare Cancers in Phase I Trials
• A Uniform Method for QT Monitoring Is Needed
• ABECMA
• ABRAXANE
• ADCETRIS
• Additional Method of Administration Approved for Cinvanti in Chemotherapy-Induced Nausea and Vomiting
• Addressing the Need for Palliative Care Integration Into Phase 1 Clinical Trials
• Adherence to Topical Management of Hand-Foot Skin Reaction Poor Among Patients Treated With Regorafenib
• AFINITOR
• AFINITOR DISPERZ
• ALECENSA
• ALIMTA
• ALIQOPA
• ALUNBRIG
• ALYMSYS
• ARIMIDEX
• AROMASIN
• ARRANON
• ARZERRA
• ASCO Integrates Results from TAILORx into ASCO Clinical Practice Guideline
• ASPARLAS
• ASTRO Releases Consensus Statement on Improving Prior Authorization
• AVASTIN
• AYVAKIT
• AZEDRA
• BALVERSA
• BAVENCIO
• BELEODAQ
• BENDEKA
• BESPONSA
• BESREMI
• BEXXAR
• BICNU
• Biosimilars Mvasi, Kanjinti Now Available in the US
• BLENREP
• Bleomycin
• BLINCYTO
• Bone Health Management Key in Childhood Cancer Survivors
• BOSULIF
• BRAFTOVI
• BREYANZI
• BRUKINSA
• Burden of Obesity-Associated Cancers Shifted to Younger Age Groups
• BUSULFEX
• BYNFEZIA PEN
• BYNFEZIA PEN
• CABOMETYX
• California Couple Awarded $2 Billion in Roundup Lawsuit
• CALQUENCE
• CAMCEVI
• CAMPATH
• CAMPTOSAR
• Cancer Diagnosis Linked to Less Aggressive Treatment for Cardiac Arrest in Hospitalized Patients
• Cancer Drugs Approved as Breakthrough Therapies Have Comparable Clinical Benefit to Those Approved Under FDA’s Standard Regulatory Pathway
• Cancer Risks Examined in Rheumatoid Arthritis Patients
• Cancer Survivors Have High Prevalence of Chronic Pain
• Cannabis Legalization Not Tied to Higher Health Care Utilization
• Cannabis Products Used Differ for Cancer, Noncancer Patients
• CAPRELSA
• Carboplatin
• Caregiving for Older Cancer Patients Takes Emotional Toll
• CARVYKTI
• CASODEX
• CDC Clarifies Position on Use of Opioids in Patients With Cancer
• CERUBIDINE
• Checklist Ensures Adherence to Recommended CAR-T Cell Administration Processes
• Cisplatin
• Cladribine
• Clinical Decision Aid Helps Standardize the Management of Febrile Neutropenia
• Clinical Pathway Program Promotes Clinical Trial Enrollment
• Clinical Photography Enhances Tumor Assessment Documentation
• Clinical Practice Guideline Update Focuses on Prevention and Management of Medication-Related Osteonecrosis of the Jaw
• Clinical Trials for Cancer Therapies Lack Data on Patients With Cardiovascular Disease
• CLOLAR
• CMS Increases Reimbursement Rate for Product Cost of CAR-T Therapy
• COMETRIQ
• Common Cancers May Be Underfunded; Stigma to Blame
• Comparing Survivorship Care Plan and Visit Utility and Effectiveness
• COPIKTRA
• Coronary Calcification an Underused CV Risk Marker Following Cancer Treatment
• COSELA
• COSMEGEN
• COTELLIC
• CRISPR–Cas9 Gets a Rebrand: Meet Cas9–gRNA
• Cyclophosphamide
• Cyclophosphamide Injection
• CYRAMZA
• Cytarabine
• Dacarbazine
• DACOGEN
• DANYELZA
• DARZALEX
• DARZALEX FASPRO
• DAURISMO
• Declining Use of Chemotherapy in the Last 2 Weeks of Life for Older Patients With Solid Tumor Cancers
• DELESTROGEN
• DEPO-PROVERA
• DEPOCYT
• DOXIL
• Doxorubicin HCl
• Doxorubicin HCl Solution
• Early MRD Status After CAR-T Administration Predicted PFS, OS
• EFUDEX
• EFUDEX CREAM
• ELAHERE
• ELIGARD
• ELLENCE
• ELOXATIN
• ELZONRIS
• EMCYT
• EMPLICITI
• ENHERTU
• ERBITUX
• ERIVEDGE
• ERLEADA
• ERWINAZE
• ESMO Releases Recommendations on MSI Testing for Immunotherapy
• Estimated Benefit of Checkpoint Inhibitors in Cancer Is “Sobering”
• ESTRACE
• ETHYOL
• ETOPOPHOS
• Etoposide Capsules
• Evidence Supporting NCCN Off-Label Recommendations Is Robust: Study
• EVISTA
• EVOMELA
• EXKIVITY
• Facilitating CAR-T Cell Therapy in Solid Tumors Through “Vaccine Boosting”
• FARESTON
• FARYDAK
• FASLODEX
• Female Representation on NCCN Guideline Panels Suggests Low Gender Bias
• FEMARA
• Few Oncologists Refer Patients to Weight Management Programs
• Fifteen Million Patients Will Need First-Course Chemo in 2040
• FIRMAGON
• Floxuridine
• Fludarabine
• Fluorouracil
• Fluorouracil Injection Recalled Due to Glass Particulate
• Flutamide
• FOLOTYN
• For Complex Surgeries, Flagship Cancer Hospitals Found Safer Than Affiliate Locations
• FOTIVDA
• FUSILEV
• FYARRO
• GAVRETO
• GAZYVA
• Gemcitabine
• Genetic-Specific Navigator Helps Patients, Nongenetic Health Care Providers
• GILOTRIF
• Gilteritinib Prolongs OS Compared With Salvage Chemotherapy in Patients With FLT3-Mutated Relapsed/Refractory AML
• GLEEVEC
• GLEOSTINE
• GLIADEL
• Global Burden of Childhood Cancers Examined
• HALAVEN
• Health Professionals Supportive of Medicinal Cannabis
• HERCEPTIN
• HERCEPTIN HYLECTA
• HERZUMA
• Higher Risk for Cancer, Mortality Seen With Pediatric-Onset IBD
• How Often Does the FDA Disagree With Its Advisory Committees’ Recommendations?
• How Safe Is Resumption of Checkpoint Inhibitor Therapy After an Initial Event of Immune-Mediated Diarrhea and Colitis?
• Human Germline Editing: Call for a Moratorium and Creation of an International Governance Framework
• HYCAMTIN
• HYCAMTIN CAPSULES
• HYDREA
• IBRANCE
• ICLUSIG
• IDAMYCIN PFS
• Idarubicin
• IDHIFA
• IFEX
• IMBRUVICA
• IMBRUVICA TABLETS
• IMFINZI
• IMJUDO
• IMLYGIC
• Immunotherapy Followed by Osimertinib: Increased Risk of Severe Immune-Related AEs
• Inclusion of Geriatric Assessments Alters Cancer Management in Older Patients
• Incorporating Distress Screening Improves Referrals in Telephonic Case Management for Cancer Patients
• Increased Cancer Risk Seen in Multiple Sclerosis Patients
• INFUGEM
• INLYTA
• INQOVI
• INREBIC
• INTRON A
• INTRON A SOLN
• IRESSA
• ISTODAX
• IXEMPRA
• JAKAFI
• JAYPIRCA
• JELMYTO
• JEMPERLI
• JEVTANA
• KADCYLA
• KANJINTI
• KEPIVANCE
• KEYTRUDA
• KHAPZORY
• KIMMTRAK
• KISQALI
• KISQALI FEMARA CO-PACK
• KOSELUGO
• KOSELUGO
• KRAZATI
• KYMRIAH
• KYPROLIS
• Lenvatinib Active in Rare Adenoid Cystic Carcinoma
• LENVIMA
• Leucovorin
• LEUKERAN
• Leuprolide acetate
• LEVOXYL
• LIBTAYO
• Light Therapy May Prevent Oral Mucositis for Some in Cancer Tx
• Liquid Biopsy for Detecting MSI-High Status Found Concordant With Tissue-Based Testing
• LONSURF
• LORBRENA
• LUMAKRAS
• LUMOXITI
• LUNSUMIO
• LUPRON DEPOT 7.5mg
• LUPRON DEPOT-3 MONTH 22.5mg
• LUPRON DEPOT-4 MONTH 30mg
• LUPRON DEPOT-6 MONTH 45mg
• LUTATHERA
• LYNPARZA
• LYSODREN
• LYTGOBI
• MARGENZA
• MARQIBO
• MATULANE
• Medicaid Expansion Eliminated Racial Disparities in Timeliness of Treatment Between Black and White Patients With Advanced Cancer
• Megestrol Tablets
• MEKINIST
• MEKTOVI
• Melphalan
• Melphalan Injection
• MENEST
• Mercaptopurine
• MESNEX
• MESNEX INJECTION
• Methotrexate for Injection
• Methotrexate Injection
• Methotrexate Tablets
• Mitomycin
• Mitoxantrone HCl
• MVASI
• MYLERAN
• NCI Pediatric MATCH Study Shows High Rate of Targetable Molecular Alterations in Tumor Specimens
• Nearly Half of NCI Cancer Center Physician Directors Received Industry Payments Between 2015 and 2017
• NERLYNX
• News Is Good and Bad for Oncology Patient Navigation Studies
• NEXAVAR
• NILANDRON
• NINLARO
• Non-Somatic PHQ-9 Items Accurately Identify Major Depressive Disorder in Patients With Cancer
• Novel Metric Sheds Light on When Adverse Events May Occur
• NUBEQA
• ODOMZO
• OGIVRI
• ONCASPAR
• ONIVYDE
• ONTAK
• ONTRUZANT
• OPDIVO
• OPDUALAG
• ORGOVYX
• ORSERDU
• Out-of-Network Billing Common for Privately Insured Patients Receiving In-Network Care
• Outcomes With a 12-Week Schedule of Zoledronic Acid for Treatment of Bone Metastasis
• Outcomes Worse for Cancer Patients Seen at Noncancer EDs
• Overall Cancer Survival Rates Up Among Adolescents, Young Adults
• Paclitaxel
• PADCEV
• Pamidronate Disodium Injection
• PANRETIN
• Patient Diversity in Clinical Trials: Best Practices for Accrual
• PEDMARK
• PEMAZYRE
• PEMAZYRE
• PEMFEXY
• Pentostatin
• PERJETA
• Phase 2 Trial Assessed Feasibility of Enterade for Diarrhea Prevention After ASCT for MM or NHL
• Phase 3 Trial Compares Standard-Dose Versus High-Dose Combination Chemo With Stem Cell Transplant for Germ Cell Tumors
• PHOTOFRIN
• PIQRAY
• PLUVICTO
• POLIVY
• POMALYST
• PORTRAZZA
• POTELIGEO
• Potential Factors Associated With Early Mortality With Immunotherapy
• PREMARIN
• Private Insurers Pay 241 Percent of What Medicare Would Pay
• PROGLYCEM SUSPENSION
• PROLEUKIN
• Promising Early Results for Preoperative Atezolizumab in Resectable NSCLC
• Proposed CMS Rule Change Would Restrict Access to Anticancer Medications
• PROVENGE
• PURIXAN
• QINLOCK
• QUADRAMET
• Quality of End-of-Life Care Found to Be Worse at Cancer Centers Serving Minority Populations
• Quality of Voluntary, Pharmaceutical-Sponsored Postapproval Clinical Trials Varied Widely
• RETEVMO
• Review: Medications Linked to Hyperlactatemia, Lactic Acidosis
• REVLIMID
• REZLIDHIA
• RIABNI
• Risk for Cancer Increased in Men, Women With T2DM
• Risk for Cardiovascular Disease Greater for Childhood Cancer Survivors
• RITUXAN
• RITUXAN HYCELA
• ROZLYTREK
• Rozlytrek, a Tumor Agnostic Therapy, Receives FDA Approval
• RUBRACA
• RUXIENCE
• RYDAPT
• SANDOSTATIN
• SANDOSTATIN LAR DEPOT
• SARCLISA
• SCEMBLIX
• SENSIPAR
• SOLTAMOX
• SOMATULINE DEPOT
• SPRYCEL
• State-Level Variation Noted in Economic Burden of Cancer
• STIVARGA
• Study Confirms Teratogenicity of Valproic Acid, Topiramate
• Substantial Variation in Chemotherapy Infusion Practices Seen at Large Cancer Centers
• Survey Underscores Need for Formal Adverse Event Attribution Training in Oncology
• SUTENT
• SYLATRON
• SYNRIBO
• Synthetic Control Arm Replicates Outcomes From Historical Data
• SYNTHROID
• TABRECTA
• TAFINLAR
• Tafinlar Plus Mekinist Approved for Pediatric BRAF V600E Low-Grade Glioma
• TAGRISSO
• TALZENNA
• Tamoxifen
• TARCEVA
• TARGRETIN
• TARGRETIN GEL
• TASIGNA
• TAXOTERE
• TAZVERIK
• TECARTUS
• TECENTRIQ
• TECVAYLI
• Telerehabilitation Aids Function, Pain With Advanced Cancer
• TEMODAR
• TEMODAR INJECTION
• Teniposide
• TEPADINA
• TEPMETKO
• Testosterone Enanthate
• THALOMID
• The Predictive Ability of a Cancer Subtype Ontology Assignment
• Thioguanine
• Thiotepa
• THYQUIDITY
• THYROGEN
• TIBSOVO
• TICE BCG
• TIROSINT-SOL
• TIVDAK
• Toolbox Enables Quick Response to Anticancer Therapy-Induced Hypersensitivity Reactions
• TOPOSAR
• TORISEL
• TOTECT
• TRAZIMERA
• TREANDA
• Treatment Patterns for Imminently Fatal Cancers Varied by Cancer Type
• TRELSTAR
• Tretinoin
• TREXALL
• TRISENOX
• TRODELVY
• TRUXIMA
• TUKYSA
• TURALIO
• TYKERB
• Ulenistamab Fast Tracked for Advanced/Metastatic Pancreatic Cancer
• UNITHROID
• UNITUXIN
• Use of Pathogenic BRCA1/2 Alterations as Pan-Cancer Biomarkers for Therapy Selection May Not be Appropriate
• UVADEX
• VALCHLOR
• VALSTAR
• Value Frameworks Back Checkpoint Inhibitor Approvals in Palliative Setting
• Variant Calling Best Practices Benefit the Cancer Diagnostic Community
• VECTIBIX
• VELCADE
• VENCLEXTA
• VERZENIO
• VIDAZA
• Vinblastine For Injection
• Vinblastine Injection
• Vincristine Sulfate PFS
• Vinorelbine
• Vitiligo May Be Associated With Reduced Risk of Internal Cancer
• VITRAKVI
• VITRAKVI ORAL SOLUTION
• VIZIMPRO
• VONJO
• VORAXAZE
• VOTRIENT
• VYXEOS
• WELIREG
• Worse Cancer Outcomes for Elderly HIV-Infected Patients
• XALKORI
• XATMEP
• XELODA
• XERMELO
• XGEVA
• XOFIGO
• XOSPATA
• XPOVIO
• XTANDI
• YERVOY
• YESCARTA
• YONDELIS
• YONSA
• Young Male Adults Have Lower Cancer Burden Than Women
• ZALTRAP
• ZANOSAR
• ZEJULA
• ZELBORAF
• ZEPZELCA
• ZEVALIN
• ZINECARD
• ZIRABEV
• ZOLADEX
• ZOLADEX 3-MONTH 10.8mg
• ZOLINZA
• ZOMETA
• ZYDELIG
• ZYKADIA
• ZYNLONTA
• ZYTIGA